Brepocitinib

About Roivant Sciences

Roivant Sciences' mission is to improve health by rapidly delivering innovative medicines through its unique 'Vant' model—nimble, entrepreneurial subsidiaries. The company has demonstrated significant execution with 12 positive Phase 3 trials, 8 FDA approvals, and a successful commercial launch of VTAMA® for plaque psoriasis, which was subsequently acquired by Organon in 2024. Its strategy centers on decentralized decision-making, specialized expertise, and disciplined capital allocation to de-risk development and maximize value creation across a broad pipeline in autoimmune, pulmonary, and other diseases.

About Roivant Sciences

Roivant Sciences' mission is to improve health by rapidly delivering innovative medicines through its unique 'Vant' model—nimble, entrepreneurial subsidiaries. The company has demonstrated significant execution with 12 positive Phase 3 trials, 8 FDA approvals, and a successful commercial launch of VTAMA® for plaque psoriasis, which was subsequently acquired by Organon in 2024. Its strategy centers on decentralized decision-making, specialized expertise, and disciplined capital allocation to de-risk development and maximize value creation across a broad pipeline in autoimmune, pulmonary, and other diseases.

Therapeutic Areas